AURKA and neoplasm: We demonstrated higher expression of Aurora-A in tumors from the youngest breast cancer patients (below 40 years) compared to the older (40-49 years), emphasizing that high levels of Aurora-A kinase protein and AURKA mRNA expression point to aggressive tumor features and associate with reduced survival in breast cancer patients below 50 years.